Capricor Therapeutics Inc
CAPRHealthcare·Biotechnology·USA·Small·NASD·Nov 13 • 7:42 AM ET
10.25+0.01 (0.10%)
2026-11-13 13:43 CET
Market cap
$595.96M
Revenue, TTM
0.00 USD m
Net income, TTM
-147.50 USD m
Free cash flow, TTM
-146.29 USD m
EPS diluted, TTM
-2.65
Price
CAPR against its 20, 50 and 200-day averagesPatternshover a marker to name it
74.6% under the 52-week high of 40.37 on 3 Dec 2025. 52-week low 2.96 on 30 Jul 2026. Last 15 sessions, 98.1% high to low
Volume 0.07× normal · the line is the 50-bar volume average
Setup. RS line 7
CANSLIM 3 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High
VCP 2 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; RSI (14): Not Overbought (<60)
Minervini 1 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Zanger 2 of 5 — fails: 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 3 of 5 — fails: 200-Day Simple Moving Average: Price above SMA200; 52-Week High/Low: 0-10% below High
Breakout 1 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 200-Day Simple Moving Average: Price above SMA200
Growth 1 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); Return on Equity: Over +15%
Quality 1 of 5 — fails: Return on Equity: Over +15%; Debt/Equity: Low (<0.1) — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 0 of 4 — fails: P/B: Under 2; Return on Equity: Over +15%; Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 3 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200
Accumulation 3 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200
Relative Strength 1 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200
Profile
CAPR52-week range, 19% of the way up
2.9640.37
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy ("DMD"), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
| Index | RUT |
|---|---|
| Employees | 231 |
| IPO | Jun 20, 2002 |
| Beta | 0.73 |
| ATR, 14d | 0.90 |
| Rel volume | 0.07 |
| Short float | 35.63% |
| Insider own | 9.44% |
| Inst own | 72.95% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | $595.96M |
| Enterprise Value | 490.61M |
| Income | -147.50M |
| Sales | 0.00M |
| Book / share | 3.61 |
| Cash / share | 3.40 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 231 |
| IPO | Jun 20, 2002 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | - |
| Price / book | 2.84 |
| Price / cash | 3.02 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | - |
| Quick Ratio | 6.77 |
| Current Ratio | 6.77 |
| Debt / equity | 0.44 |
| Long-term debt / equity | 0.43 |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -2.65 |
|---|---|
| Earnings next year | -1.47 |
| Earnings next quarter | -0.37 |
| Earnings this year | -4.87% |
| Earnings next year | 37.93% |
| Earnings growth, 5 years | 47.99% |
| Past earnings growth | -24.12% -20.84% |
| Past sales growth | - - |
| Earnings vs last year | -47.08% |
| Sales vs last year | -100.00% |
| Earnings vs last quarter | -36.52% |
| Sales vs last quarter | - |
| Earnings | Nov 10 AMC |
| Surprise | -66.36% -100.00% |
Ownership
| Insiders own | 9.44% |
|---|---|
| Insider trades | -0.90% |
| Institutions own | 72.95% |
| Institution trades | 12.24% |
| Return on assets | -64.58% |
| Return on equity | -100.47% |
| Return on capital | -49.09% |
| Gross Margin | - |
| Operating margin | - |
| Profit Margin | - |
| 20-day average | 32.51% |
| 50-day average | 26.31% |
| 200-day average | -48.85% |
Technical
| Shares out | 58.14M |
|---|---|
| Shares floating | 52.66M |
| Short / float | 35.63% |
| Short ratio | 3.05 |
| Short interest | 18.77M |
| 52-week high | 40.37 -74.6% |
| 52-week low | 2.96 +246.3% |
| Volatility | 15.30% 10.94% |
| Average range | 0.90 |
| Strength index | 62.01 |
| Market sensitivity | 0.73 |
| Relative volume | 0.07 |
| Avg Volume | 6.15M |
| Volume | 20,797 |
Performance
| Perf Week | 13.89% |
|---|---|
| Perf Month | 40.99% |
| Perf Quarter | 37.58% |
| Perf Half Y | -64.40% |
| Perf YTD | -64.48% |
| Perf Year | 77.64% |
| Perf 3Y | 260.92% |
| Perf 5Y | 196.24% |
| Perf 10Y | -62.32% |
| Recommendation | 1.89 |
| Target Price | 27.25 |
| Prev Close | 10.24 |
| Price | 10.25 |
| Change % | 0.10% |
Analyst ratings
latest 10 of 20| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Nov 11, 2026 | Upgrade | Jones Trading | Hold → Buy | $25 | +143.9% |
| Sep 14, 2026 | Upgrade | B. Riley Securities | Neutral → Buy | $21 | +104.9% |
| Sep 01, 2026 | Upgrade | Piper Sandler | Neutral → Overweight | $25 | +143.9% |
| Aug 25, 2026 | Upgrade | Oppenheimer | Perform → Outperform | $54 | +426.8% |
| Aug 14, 2026 | Upgrade | Cantor Fitzgerald | Neutral → Overweight | $28 | +173.2% |
| Jul 30, 2026 | Downgrade | Piper Sandler | Overweight → Neutral | $2 | -80.5% |
| Jul 30, 2026 | Downgrade | Oppenheimer | Outperform → Perform | ||
| Jul 30, 2026 | Downgrade | Maxim Group | Buy → Hold | ||
| Jul 30, 2026 | Downgrade | Ladenburg Thalmann | Buy → Neutral | ||
| Jul 30, 2026 | Downgrade | H.C. Wainwright | Buy → Neutral |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| SRPT | Sarepta Therapeutics Inc | 1.74B |
| SLDB | Solid Biosciences Inc | 771.23M |
| WVE | Wave Life Sciences Inc | 639.02M |
| DYN | Dyne Therapeutics Inc | 3.19B |
| EWTX | Edgewise Therapeutics Inc | 4.98B |
| MESO | Mesoblast Ltd ADR | 1.70B |
| PEPG | PepGen Inc | 349.84M |
| TNYA | Tenaya Therapeutics Inc | 84.09M |
| BCDA | BioCardia Inc | 12.50M |
| LGVN | Longeveron Inc | 9.18M |
Insider trading
latest 14 of 35| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Krasney Karen | EVP, GENERAL COUNSEL | Jun 25 '26 | Option Exercise | 3.18 | 24,100 | 76,638 | 54,647 | Jun 29 09:30 PM |
| Krasney Karen | EVP, GENERAL COUNSEL | Jun 25 '26 | Sale | 30.38 | 24,100 | 732,158 | 30,547 | Jun 29 09:30 PM |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER | Jun 25 '26 | Option Exercise | 3.18 | 24,100 | 76,638 | 35,323 | Jun 29 09:30 PM |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER | Jun 25 '26 | Sale | 30.38 | 24,100 | 732,158 | 11,223 | Jun 29 09:30 PM |
| Krasney Karen | EVP, GENERAL COUNSEL | Jun 22 '26 | Option Exercise | 3.18 | 500 | 1,590 | 31,047 | Jun 24 08:00 PM |
| Krasney Karen | EVP, GENERAL COUNSEL | Jun 24 '26 | Option Exercise | 3.18 | 400 | 1,272 | 30,947 | Jun 24 08:00 PM |
| Krasney Karen | EVP, GENERAL COUNSEL | Jun 22 '26 | Sale | 30.00 | 500 | 15,000 | 30,547 | Jun 24 08:00 PM |
| Krasney Karen | EVP, GENERAL COUNSEL | Jun 24 '26 | Sale | 30.00 | 400 | 12,000 | 30,547 | Jun 24 08:00 PM |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER | Jun 22 '26 | Option Exercise | 3.18 | 500 | 1,590 | 11,723 | Jun 24 08:00 PM |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER | Jun 24 '26 | Option Exercise | 3.18 | 400 | 1,272 | 11,623 | Jun 24 08:00 PM |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER | Jun 22 '26 | Sale | 30.00 | 500 | 15,000 | 11,223 | Jun 24 08:00 PM |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER | Jun 24 '26 | Sale | 30.00 | 400 | 12,000 | 11,223 | Jun 24 08:00 PM |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER | May 18 '26 | Option Exercise | 1.39 | 3,000 | 4,170 | 11,223 | May 19 04:15 PM |
| Musket David B | Director | May 19 '26 | Proposed Sale | 27.00 | 88,788 | 2,397,256 | May 19 11:40 AM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| XBI | State Street SPDR S&P Biotech ETF | AUM: 10.59B |
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 696.31B |
| IWM | iShares Russell 2000 Index Fund | AUM: 77.86B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
| IWO | iShares Russell 2000 Growth ETF | AUM: 14.25B |
| VTWO | Vanguard Russell 2000 Index ETF | AUM: 16.90B |
| VHT | Vanguard Health Care ETF | AUM: 21.54B |
| LABU | Direxion Daily S&P Biotech Bull 3X ETF | AUM: 597.74M |
| ITOT | iShares Core S&P Total U.S. Stock Market ETF | AUM: 96.50B |
| VTWG | Vanguard Russell 2000 Growth Index ETF | AUM: 1.43B |
News
latest 14 of 200- CAPR Stock Rallies: Investors Scrutinize Labeling Hints Before FDA Decision On Cell Therapy This Month (Stocktwits) +26.49%
- CAPR Stock Rallies After-Hours As Capricor Reaffirms Deramiocel Confidence Ahead Of Nov. 22 Decision; Says Application In Final Review (Stocktwits) -9.95%
- Capricor Misses As Pre-Launch Spending Climbs; Data Package Is Rebuilt, But The November 22 FDA Decision Now Rests On A Narrower Indication (Earnings Whispers)
- Capricor: Q3 Earnings Snapshot (Associated Press)
- Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
- CAPR Stock Edges Higher Ahead Of Q3 Earnings, But Retails Attention Remains Firmly Fixed On Nov. 22 FDA Decision For Deramiocel (Stocktwits)
- US Stock Futures Mixed As Investors Await CPI Data AMD, CRWV, RKLB Stocks In Focus (Stocktwits)
- CAPR Stock Rises After Deramiocel Cardiac Data Wins American Heart Association Award Ahead Of FDA Decision (Stocktwits) +9.44%
- Capricor's HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology (GlobeNewswire)
- Capricor's Q3 Report Must Show Whether Its Narrower FDA Path For Deramiocel Is Holding (Earnings Whispers) +8.25%
- CAPR Stock Rises As Clinical Trial Investigators Write To FDA Urging Approval For Deramiocel (Stocktwits) +13.81%
- Capricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10 (GlobeNewswire)
- FDA Decision Watch: Regeneron And Roches Autoimmune Drugs, Capricors DMD Therapy In Spotlight (Stocktwits) +13.48%
- CAPR Stock Rallies Into FDA Decision Month: Retail Spots Approval Tea Leaves In Capricors Launch Team Hiring (Stocktwits)
Quarterly earnings
2026Q3 EPS -0.730 missed -0.439, from -0.540 a year earlier. Sales 0.00 missed 15.33, from 0.00 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q3ended 2026-09-30 | 2026-11-10 16:30 | -0.730 | -0.439 | -0.730 | 0.00 | 15.33 | EPS +66.4% · sales -100.0% | vs 2025Q3, year-ago quarter · EPS +35.2% · sales - | 8 EPS · 6 sales | Open +8.79% vs SPY +0.92%. Close +26.49% vs SPY +1.32% |
| 2026Q2ended 2026-06-30 | 2026-08-13 16:30 | -0.700 | -0.589 | -0.703 | 0.00 | 0.00 | EPS +18.9% · sales - | vs 2025Q2, year-ago quarter · EPS +22.8% · sales - | 9 EPS · 8 sales | Open +81.95% vs SPY +0.08%. Close +57.96% vs SPY -0.20% |
| 2026Q1ended 2026-03-31 | 2026-05-12 16:30 | -0.590 | -0.523 | -0.591 | 0.00 | 0.00 | EPS +12.8% · sales - | vs 2025Q1, year-ago quarter · EPS +11.3% · sales - | 7 | Open -2.69% vs SPY +0.04%. Close -3.78% vs SPY +0.56% |
| 2025Q4ended 2025-12-31 | 2026-03-12 16:30 | -0.620 | -0.509 | -0.618 | 0.00 | 0.53 | EPS +21.8% · sales -100.0% | vs 2024Q4, year-ago quarter · EPS +287.5% · sales -100.0% | 10 EPS · 8 sales | Open -1.26% vs SPY +0.48%. Close -8.74% vs SPY -0.57% |
| 2025Q3ended 2025-09-30 | 2025-11-10 16:30 | -0.540 | -0.547 | -0.538 | 0.00 | 0.60 | EPS -1.2% · sales -100.0% | vs 2024Q3, year-ago quarter · EPS +42.1% · sales -100.0% | 9 EPS · 8 sales | Open +5.94% vs SPY -0.22%. Close +11.51% vs SPY +0.23% |
| 2025Q2ended 2025-06-30 | 2025-08-11 16:30 | -0.570 | -0.476 | -0.567 | 0.00 | 1.42 | EPS +19.7% · sales -100.0% | vs 2024Q2, year-ago quarter · EPS +62.9% · sales -100.0% | 10 EPS · 9 sales | Open +0.45% vs SPY +0.37%. Close +2.88% vs SPY +1.06% |
| 2025Q1ended 2025-03-31 | 2025-05-13 16:30 | -0.530 | -0.317 | -0.535 | 0.00 | 3.16 | EPS +67.4% · sales -100.0% | vs 2024Q1, year-ago quarter · EPS +71.0% · sales -100.0% | 6 | Open +6.03% vs SPY +0.17%. Close +5.07% vs SPY +0.13% |
| 2024Q4ended 2024-12-31 | 2025-03-19 16:30 | -0.160 | -0.170 | -0.160 | 11.13 | 3.52 | EPS -5.9% · sales +216.0% | vs 2023Q4, year-ago quarter · EPS +700.0% · sales -7.9% | 7 EPS · 4 sales | Open +2.78% vs SPY -0.67%. Close +17.51% vs SPY -0.29% |
| 2024Q3ended 2024-09-30 | 2024-11-13 16:30 | -0.380 | -0.358 | -0.380 | 2.26 | 4.28 | EPS +6.1% · sales -47.2% | vs 2023Q3, year-ago quarter · EPS +52.0% · sales -63.4% | 6 EPS · 5 sales | Open +0.06% vs SPY +0.02%. Close +9.34% vs SPY -0.64% |
| 2024Q2ended 2024-06-30 | 2024-08-07 16:30 | -0.350 | -0.356 | -0.345 | 3.97 | 4.58 | EPS -1.7% · sales -13.3% | vs 2023Q2, year-ago quarter · EPS +20.7% · sales +1.4% | 5 EPS · 4 sales | Open +12.92% vs SPY +1.01%. Close +8.99% vs SPY +2.31% |
| 2024Q1ended 2024-03-31 | 2024-05-13 16:30 | -0.310 | -0.114 | -0.312 | 4.91 | 9.70 | EPS +172.6% · sales -49.4% | vs 2023Q1, year-ago quarter · EPS 0.0% · sales +64.3% | 3 | Open -5.70% vs SPY +0.04%. Close -4.41% vs SPY +0.46% |
| 2023Q4ended 2023-12-31 | 2024-02-29 16:30 | -0.020 | -0.090 | -0.025 | 12.09 | 10.60 | EPS -77.8% · sales +14.0% | vs 2022Q4, year-ago quarter · EPS -93.5% · sales +1159.3% | 3 | Open +5.48% vs SPY +0.18%. Close +8.69% vs SPY +0.94% |
| 2023Q3ended 2023-09-30 | 2023-11-14 16:30 | -0.250 | -0.303 | -0.248 | 6.19 | 3.15 | EPS -17.6% · sales +96.4% | vs 2022Q3, year-ago quarter · EPS -3.8% · sales +288.7% | 3 EPS · 2 sales | - |
| 2023Q2ended 2023-06-30 | 2023-08-07 16:30 | -0.290 | -0.350 | -0.291 | 3.92 | 3.00 | EPS -17.1% · sales +30.6% | vs 2022Q2, year-ago quarter · EPS 0.0% · sales - | 2 EPS · 1 sales | - |
| 2023Q1ended 2023-03-31 | 2023-05-11 16:30 | -0.310 | -0.320 | -0.308 | 2.99 | 1.00 | EPS -3.1% · sales +198.7% | vs 2022Q1, year-ago quarter · EPS -3.1% · sales - | 2 EPS · 1 sales | - |
| 2022Q4ended 2022-12-31 | 2023-03-15 16:30 | -0.310 | -0.340 | -0.307 | 0.96 | 0.01 | EPS -8.8% · sales +9499.0% | vs 2021Q4, year-ago quarter · EPS +19.2% · sales - | 3 EPS · 1 sales | - |
Annual earnings
2025FY EPS -2.260 missed -2.132, from -1.150 a year earlier. Sales 0.00 missed 0.66, from 22.27 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | 1.912 | - | - | 478.67 | 5.36 |
| 2029FYestimate | - | 0.412 | - | - | 416.82 | 24.88 |
| 2028FYestimate | - | -0.318 | - | - | 285.78 | - |
| 2027FYestimate | - | -1.471 | - | - | 91.36 | - |
| 2026FYestimate | - | -2.370 | - | - | 52.79 | - |
| 2025FY | -2.260 | -2.132 | -2.260 | 0.00 | 0.66 | - |
| 2024FY | -1.150 | -1.190 | -1.149 | 22.27 | 20.97 | - |
| 2023FY | -0.830 | -1.040 | -0.832 | 25.18 | 21.05 | - |
| 2022FY | -1.180 | -1.217 | -1.182 | 2.55 | 1.59 | - |
| 2021FY | -0.870 | -0.800 | -0.867 | 0.24 | 0.22 | - |
| 2020FY | -0.880 | -0.880 | -0.877 | 0.31 | 0.25 | - |
| 2019FY | -2.060 | -1.965 | -2.059 | 1.01 | 0.84 | - |
| 2018FY | -5.200 | -5.750 | -5.165 | 1.67 | 1.16 | - |
| 2017FY | 0.900 | -5.400 | 0.908 | 2.67 | 2.80 | 17.56 |
| 2016FY | -10.100 | -9.850 | -10.100 | 4.00 | 4.10 | - |
| 2015FY | -8.100 | -8.000 | -8.100 | 5.52 | 5.49 | - |
| 2014FY | -5.300 | - | -5.300 | 4.79 | - | - |
| 2010FY | -95.000 | -95.000 | -95.000 | 0.00 | 0.00 | - |
Quarterly results
2026Q3 revenue 0.00, from 0.00 a year earlier. 2024Q4 operating margin -69.2%, from -8.8% a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -2.37 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-11-11 | -2.37 | +29.2% |
| 2026Q4 | E | per share | 2026-11-11 | -0.37 | -31.3% |
| 2026FY | R | per share | 2026-11-11 | -2.45 | +18.9% |
| 2026Q4 | R | per share | 2026-11-11 | -0.47 | -0.4% |
| 2026FY | S | per share | 2026-11-11 | 52.79 | -31.6% |
| 2026Q4 | S | per share | 2026-11-11 | 52.76 | +18.3% |
| 2026Q3 | E | per share | 2026-11-07 | -0.44 | 0.0% |
| 2026Q3 | S | per share | 2026-11-06 | 15.33 | -63.2% |
| 2026Q3 | R | per share | 2026-10-28 | -0.28 | +6.8% |
| 2026Q2 | E | per share | 2026-07-29 | -0.59 | -3.7% |
| 2026Q2 | R | per share | 2026-07-29 | -0.57 | -6.7% |
| 2026Q2 | S | per share | 2026-05-13 | 0.00 | - |
| 2026Q1 | E | per share | 2026-05-08 | -0.51 | -5.4% |
| 2026Q1 | R | per share | 2026-04-21 | -0.48 | +0.2% |
| 2026Q1 | S | per share | 2026-03-13 | 0.00 | - |
| 2025FY | E | per share | 2026-02-22 | -2.13 | 0.0% |
| 2025Q4 | E | per share | 2026-02-22 | -0.51 | 0.0% |
| 2025FY | R | per share | 2026-02-18 | -2.19 | 0.0% |
| 2025Q4 | R | per share | 2026-02-18 | -0.55 | 0.0% |
| 2025FY | S | per share | 2026-01-25 | 0.66 | 0.0% |
| 2025Q4 | S | per share | 2026-01-25 | 0.53 | 0.0% |
| 2025Q3 | E | per share | 2025-10-26 | -0.55 | 0.0% |
| 2025Q3 | R | per share | 2025-10-26 | -0.55 | 0.0% |
| 2025Q3 | S | per share | 2025-10-26 | 0.60 | 0.0% |
| 2025Q2 | E | per share | 2025-07-28 | -0.48 | 0.0% |
| 2025Q2 | R | per share | 2025-07-28 | -0.47 | 0.0% |
| 2025Q2 | S | per share | 2025-07-28 | 1.42 | 0.0% |
| 2025Q1 | E | per share | 2025-03-28 | -0.32 | -1.0% |
| 2025Q1 | R | per share | 2025-03-28 | -0.31 | +7.8% |
| 2025Q1 | S | per share | 2025-03-27 | 3.16 | -16.7% |
| 2024FY | E | per share | 2025-03-16 | -1.19 | -4.5% |
| 2024Q4 | E | per share | 2025-03-16 | -0.17 | -28.0% |
| 2024FY | R | per share | 2025-03-16 | -1.13 | +3.7% |
| 2024Q4 | R | per share | 2025-03-16 | -0.12 | -3.3% |
| 2024FY | S | per share | 2025-03-10 | 14.64 | 0.0% |
| 2024Q4 | S | per share | 2025-01-28 | 3.52 | -69.4% |
| 2024Q3 | E | per share | 2024-10-22 | -0.36 | 0.0% |
| 2024Q3 | S | per share | 2024-10-18 | 4.28 | -4.4% |
| 2024Q3 | R | per share | 2024-09-23 | -0.36 | -3.4% |
| 2024Q2 | E | per share | 2024-07-28 | -0.36 | 0.0% |
| 2024Q2 | R | per share | 2024-07-28 | -0.36 | 0.0% |
| 2024Q2 | S | per share | 2024-05-15 | 4.58 | +3.9% |
| 2024Q1 | E | per share | 2024-03-11 | -0.11 | -50.6% |
| 2024Q1 | R | per share | 2024-03-11 | -0.26 | +4.0% |
| 2024Q1 | S | per share | 2024-03-11 | 9.70 | +37.6% |
| 2023FY | E | per share | 2024-01-29 | -1.04 | 0.0% |
| 2023FY | R | per share | 2024-01-29 | -1.07 | 0.0% |
| 2023FY | S | per share | 2024-01-29 | 21.05 | 0.0% |
Estimate history
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS per share | 0.908 | -5.165 | -2.059 | -0.877 | -0.867 | -1.182 | -0.832 | -1.149 | -2.26 | -2.6456 | - |
| Sales USD millions | 3 | 2 | 1 | 0 | 0 | 3 | 25 | 22 | 0 | 0 | - |
| Shares million shares | 3 | 3 | 5 | 21 | 24 | 25 | 31 | 46 | 57 | - | 58 |
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.38 | -0.16 | -0.535 | -0.567 | -0.538 | -0.618 | -0.591 | -0.703 | -0.734 |
| Sales USD millions | 2 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shares million shares | 40 | 46 | 46 | 46 | 46 | 57 | 58 | 58 | 58 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00-100.0% | 22.27-11.6% | 25.18+887.5% | 2.55+962.5% | 0.24-22.6% | 0.31-69.3% | 1.01-39.5% | 1.67 |
| Cost of Goods Sold Incl. D&A | 2.56 | 1.89+32.2% | 1.43+33.6% | 1.07+55.1% | 0.69+176.0% | 0.25 | - | - | - |
| Gross Profit | -2.56 | -1.89-109.1% | 20.85-13.5% | 24.11+1196.2% | 1.86 | -0.00 | - | - | - |
| Selling, General and Administrative Excl. Other | 151.00 | 106.25+67.6% | 63.41+31.6% | 48.19+52.7% | 31.55+50.7% | 20.94+51.1% | 13.86+61.7% | 8.57-49.2% | 16.87 |
| Research and Development | 107.50 | 83.50+69.7% | 49.19+37.3% | 35.82+64.2% | 21.82+60.8% | 13.57+60.4% | 8.46+64.6% | 5.14-57.4% | 12.07 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -153.56 | -108.14 | -42.56 | -24.08 | -29.70 | -20.94 | -13.69 | -7.73 | -15.36 |
| Interest Expense | - | 3.05 | - | - | - | - | - | - | - |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.32 | - | - | 0.00 |
| Net Income Before Taxes | -147.50 | -105.04 | -40.47 | -22.29 | -29.02 | -20.02 | -13.66 | -7.64 | -15.19 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -147.50 | -105.04 | -40.47 | -22.29 | -29.02 | -20.02 | -13.66 | -7.64 | -15.19 |
| Net Income From Continuing Operations | -147.50 | -105.04 | -40.47 | -22.29 | -29.02 | -20.02 | -13.66 | -7.64 | -15.19 |
| Net Income | -147.50 | -105.04 | -40.47 | -22.29 | -29.02 | -20.02 | -13.66 | -7.64 | -15.19 |
| EPS (Recurring) per share | -2.54 | -2.26 | -1.15 | -0.83 | -1.18 | -0.88 | -0.88 | -2.06 | -5.17 |
| EPS (Basic, Before Extraordinaries) per share | -2.65 | -2.26 | -1.15 | -0.83 | -1.18 | -0.87 | -0.88 | -2.06 | -5.17 |
| EPS (Diluted) per share | -2.65 | -2.26 | -1.15 | -0.83 | -1.18 | -0.87 | -0.88 | -2.06 | -5.17 |
| EBITDA | -151.00 | -106.25 | -41.14 | -23.01 | -29.00 | -20.69 | -13.55 | -7.56 | -15.20 |
| Non-Operating Income (Expense) | 9.10 | 6.15+192.9% | 2.10+17.3% | 1.79+163.2% | 0.68+13.3% | 0.60+1900.0% | 0.03-66.7% | 0.09-47.1% | 0.17 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 17.04 | 13.61+76.5% | 7.71+4.3% | 7.39+65.7% | 4.46+50.2% | 2.97+52.3% | 1.95+178.6% | 0.70-58.1% | 1.67 |
| Price To Sales Ratio ratio | - | - | 21.82 | 5.20 | 37.14 | 276.24 | 172.15 | 4.73 | 7.21 |
| Gross Margin % | - | - | 93.60 | 95.75 | 72.77 | -0.33 | - | - | - |
| Operating Margin % | - | - | -191.12 | -95.63 | -1,163.93 | -8,549.86 | -4,412.56 | -769.52 | -918.84 |
| Net Margin % | - | - | -181.71 | -88.52 | -1,137.37 | -8,175.86 | -4,401.94 | -760.36 | -908.91 |
| Shares Outstanding million shares | 58.14 | 57.37+25.9% | 45.58+46.3% | 31.15+23.4% | 25.24+4.3% | 24.19+17.5% | 20.58+293.5% | 5.23+66.6% | 3.14 |
| Market Capitalization | 595.38 | 595.38-5.1% | 627.48+316.7% | 150.58+54.6% | 97.43+37.7% | 70.76+0.9% | 70.13+1189.2% | 5.44-57.7% | 12.87 |
Income statement, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 11.13-7.9% |
| Cost of Goods Sold Incl. D&A | 0.96+95.9% | 0.56+14.3% | 0.53+29.3% | 0.50+31.6% | 0.49+36.1% | 0.49+36.1% | 0.41+24.2% | 0.38+22.6% |
| Gross Profit | -0.96 | -0.56 | -0.53 | -0.50-104.7% | -0.49-125.8% | -0.49-113.6% | -0.41-109.0% | 10.75-8.7% |
| Selling, General and Administrative Excl. Other | 43.72+69.5% | 42.38+55.6% | 36.24+47.4% | 28.65+55.3% | 25.79+73.0% | 27.23+79.0% | 24.58+65.6% | 18.45+43.7% |
| Research and Development | 28.96+44.0% | 28.57+31.0% | 27.10+44.9% | 22.88+59.3% | 20.11+73.2% | 21.81+77.3% | 18.70+71.2% | 14.36+47.0% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -44.68 | -42.95 | -36.77 | -29.16 | -26.28 | -27.72 | -24.98 | -7.70 |
| Interest Expense | - | - | - | 3.05 | - | - | - | - |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -42.66 | -40.73 | -33.94 | -30.17 | -24.57 | -25.91 | -24.39 | -7.12 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -42.66 | -40.73 | -33.94 | -30.17 | -24.57 | -25.91 | -24.39 | -7.12 |
| Net Income From Continuing Operations | -42.66 | -40.73 | -33.94 | -30.17 | -24.57 | -25.91 | -24.39 | -7.12 |
| Net Income | -42.66 | -40.73 | -33.94 | -30.17 | -24.57 | -25.91 | -24.39 | -7.12 |
| EPS (Recurring) per share | -0.73 | -0.70 | -0.59 | -0.62 | -0.54 | -0.57 | -0.53 | -0.16 |
| EPS (Basic, Before Extraordinaries) per share | -0.73 | -0.70 | -0.59 | -0.62 | -0.54 | -0.57 | -0.53 | -0.16 |
| EPS (Diluted) per share | -0.73 | -0.70 | -0.59 | -0.62 | -0.54 | -0.57 | -0.53 | -0.16 |
| EBITDA | -43.72 | -42.38 | -36.24 | -28.65 | -25.79 | -27.23 | -24.58 | -7.32 |
| Non-Operating Income (Expense) | 2.03+18.7% | 2.21+22.1% | 2.83+379.7% | 2.03+250.0% | 1.71+280.0% | 1.81+206.8% | 0.59+25.5% | 0.58+93.3% |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 6.10+52.5% | 4.79+31.2% | 5.92+3.1% | 0.22-90.4% | 4.00+95.1% | 3.65+69.8% | 5.74+75.5% | 2.30+23.7% |
| Price To Sales Ratio ratio | - | - | - | - | 29.61 | 33.89 | 24.94 | 27.58 |
| Gross Margin % | - | - | - | - | - | - | - | 96.62 |
| Operating Margin % | - | - | - | - | - | - | - | -69.16 |
| Net Margin % | - | - | - | - | - | - | - | -63.94 |
| Shares Outstanding million shares | 58.14+27.2% | 58.11+27.1% | 57.66+26.2% | 57.37+25.9% | 45.72+13.4% | 45.71+42.9% | 45.68+44.6% | 45.58+46.3% |
| Market Capitalization | 595.38+80.6% | 1,394.52+207.2% | 1,748.32+303.3% | 1,570.01+150.2% | 329.62-33.4% | 453.88+197.5% | 433.47+103.3% | 627.48+316.7% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 | 2017FY12/31/2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 318.13+110.0% | 151.52+283.7% | 39.49-4.7% | 41.42+18.7% | 34.89+6.8% | 32.67+230.3% | 9.89+31.2% | 7.54-49.3% | 14.87 |
| Short Term Receivables | 0.06-99.4% | 10.370.0% | 10.37+1785.5% | 0.55+41.0% | 0.39 | 0.00-100.0% | 0.15-25.0% | 0.20-41.2% | 0.34 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 4.75+216.7% | 1.50+50.0% | 1.00+8.7% | 0.92-20.7% | 1.16+14.9% | 1.01+98.0% | 0.51-29.2% | 0.72+44.0% | 0.50 |
| Total Current Assets | 322.94+97.6% | 163.39+221.3% | 50.86+18.6% | 42.89+17.7% | 36.44+8.2% | 33.68+219.5% | 10.54+24.4% | 8.47-46.1% | 15.71 |
| Net Property, Plant & Equipment | 31.85+363.6% | 6.87-9.7% | 7.61+9.7% | 6.94+50.2% | 4.62+443.5% | 0.85+93.2% | 0.44-22.8% | 0.57+54.1% | 0.37 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | - | - | - | 0.00 | 0.00 | 0.00-100.0% | 0.01-80.0% | 0.05-44.4% | 0.09 |
| Deferred Tax Assets | 4.00+123.5% | 1.79 | - | - | - | - | - | - | - |
| Other Assets | 1.16+427.3% | 0.22-18.5% | 0.270.0% | 0.27-3.6% | 0.28+211.1% | 0.09-25.0% | 0.12-20.0% | 0.15+50.0% | 0.10 |
| Total Assets | 359.95+108.9% | 172.27+193.3% | 58.73+17.2% | 50.09+21.2% | 41.33+19.4% | 34.62+211.6% | 11.11+20.1% | 9.25-43.1% | 16.27 |
| Short Term Debt Incl. Current Port. of LT Debt | 3.62+336.1% | 0.83+10.7% | 0.75+10.3% | 0.68+61.9% | 0.42+68.0% | 0.25 | 0.00 | 0.00 | 0.00 |
| Accounts Payable | 1.65-49.7% | 3.28-47.5% | 6.25+27.0% | 4.92+32.3% | 3.72+36.8% | 2.72+202.2% | 0.90-28.6% | 1.26-24.6% | 1.67 |
| Other Current Liabilities | 30.56+80.7% | 16.91-30.3% | 24.27+35.0% | 17.98 | -0.00 | -0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 35.84+70.4% | 21.03-32.7% | 31.27+32.6% | 23.59+471.2% | 4.13+39.1% | 2.97+230.0% | 0.90-28.6% | 1.26-24.6% | 1.67 |
| Long Term Debt | 14.32+258.9% | 3.99-17.9% | 4.86-7.4% | 5.25-9.9% | 5.83+69.0% | 3.45+2.1% | 3.380.0% | 3.380.0% | 3.38 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 |
| Deferred Tax Liabilities | 4.00+123.5% | 1.79 | - | - | - | - | - | - | - |
| Other Liabilities | 0.00 | 0.00 | 0.00-100.0% | 9.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 54.15+102.0% | 26.81-25.8% | 36.13-5.7% | 38.31+284.6% | 9.96+55.1% | 6.42+50.4% | 4.27-7.8% | 4.63-8.3% | 5.05 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 305.79+110.2% | 145.46+543.6% | 22.60+91.7% | 11.79-62.4% | 31.37+11.2% | 28.20+312.3% | 6.84+48.1% | 4.62-58.9% | 11.23 |
| Total Shareholders Equity | 305.79+110.2% | 145.46+543.6% | 22.60+91.7% | 11.79-62.4% | 31.37+11.2% | 28.20+312.3% | 6.84+48.1% | 4.62-58.9% | 11.23 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 305.79+110.2% | 145.46+543.6% | 22.60+91.7% | 11.79-62.4% | 31.37+11.2% | 28.20+312.3% | 6.84+48.1% | 4.62-58.9% | 11.23 |
| Total Liabilities & Stockholders Equity | 359.95+108.9% | 172.27+193.3% | 58.73+17.2% | 50.09+21.2% | 41.33+19.4% | 34.62+211.6% | 11.11+20.1% | 9.25-43.1% | 16.27 |
| Book Value Per Share per share | 5.33+67.1% | 3.19+337.0% | 0.73+55.3% | 0.47-63.8% | 1.30-5.1% | 1.37+4.6% | 1.31-10.9% | 1.47-65.6% | 4.27 |
| Tangible Book Value Per Share per share | 5.33+67.1% | 3.19+337.0% | 0.73+55.3% | 0.47-63.8% | 1.30-5.1% | 1.37+4.6% | 1.31-9.7% | 1.45-65.8% | 4.24 |
| Full-Time Employees people | 231+44.4% | 160+56.9% | 102+37.8% | 74+54.2% | 48+84.6% | 26+62.5% | 16-27.3% | 22-45.0% | 40 |
| Price to Book Ratio ratio | 2.84 | 8.15 | -70.73 | 6.18 | 2.26 | 2.50 | 0.98 | 2.79 | -9.29 |
| Return on Assets % | -39.61 | -35.04 | -40.96 | -63.48 | -52.73 | -59.73 | -75.06 | -119.05 | 13.89 |
| Return on Equity % | -46.56 | -48.16 | -129.63 | -134.49 | -67.23 | -77.95 | -133.42 | -191.78 | 67.32 |
| Return on Invested Capital % | -32.81 | -27.08 | -81.15 | -170.30 | -53.83 | -43.15 | -74.81 | -190.08 | 16.65 |
| Quick Ratio ratio | 9.01 | 7.77 | 1.63 | 1.82 | 8.82 | 11.33 | 11.74 | 6.75 | 9.40 |
| Current Ratio ratio | 9.01 | 7.77 | 1.63 | 1.82 | 8.82 | 11.33 | 11.74 | 6.75 | 9.40 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -147.50 | -105.04 | -40.47 | -22.29 | -29.02 | -20.02 | -13.66 | -7.64 | -15.19 |
| Depreciation | 2.50 | 1.89+32.2% | 1.43+33.6% | 1.07+55.1% | 0.69+176.0% | 0.25+78.6% | 0.14-17.6% | 0.17+6.3% | 0.16 |
| Other Funds (Non Cash) | 27.53 | 21.14+115.1% | 9.83+33.4% | 7.37+64.1% | 4.49+60.9% | 2.79+43.1% | 1.95+178.6% | 0.70-59.5% | 1.73 |
| Funds from Operations | -117.48 | -82.01 | -29.21 | -13.84 | -23.83 | -16.99 | -11.56 | -6.77 | -13.31 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -2.52 | 12.20 | -10.78 | -11.75-140.9% | 28.75+15872.2% | 0.18-88.1% | 1.51 | -0.06 | -0.55 |
| Cash from Operating Activities | -119.99 | -69.81 | -40.00 | -25.60-620.3% | 4.92 | -16.81 | -10.05 | -6.82 | -13.86 |
| Capital Expenditures | -26.29 | -11.72 | -1.54 | -2.05 | -3.36 | -1.20 | -0.55 | 0.00 | -0.32 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | -74.23 | 109.20 | -114.64-1701.1% | 7.16 | -31.71 | 0.00-100.0% | 5.99 | -3.00-160.1% | 4.99 |
| Purchase of Investments | -297.32 | -151.39 | -208.44 | -97.44 | -114.22 | 0.00 | -6.13 | -6.00 | -18.01 |
| Sale Or Maturity of Investments | 223.08 | 260.60+177.8% | 93.80-10.3% | 104.60+26.8% | 82.51 | 0.00-100.0% | 12.12+304.0% | 3.00-87.0% | 23.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -100.41 | 97.48 | -116.18-2373.6% | 5.11 | -35.07 | -1.20-122.1% | 5.44 | -3.00-164.2% | 4.67 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 252.47 | 248.89+62.9% | 152.77+497.2% | 25.58+425.3% | 4.87-75.9% | 20.23-38.8% | 33.06+260.1% | 9.18+34.0% | 6.85 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | 0.00 |
| Sale of Common Pref Stock | 252.47 | 248.89+62.9% | 152.77+497.2% | 25.58+425.3% | 4.87-75.9% | 20.23-38.8% | 33.06+260.1% | 9.18+34.0% | 6.85 |
| Proceedsfrom Stock Options | 237.03 | 237.03+55.6% | 152.32+496.9% | 25.52+431.7% | 4.80-76.2% | 20.17-26.2% | 27.34+198.1% | 9.17+36.7% | 6.71 |
| Issuance or Reduction of Debt, Net | -6.34 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.32 | 0.00 | 0.00 |
| Change in Long Term Debt | -6.34 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.32 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.32 | 0.00 | 0.00 |
| Reduction of Long Term Debt | -6.34 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 |
| Cash from Financing Activities | 246.13 | 248.89+62.9% | 152.77+497.2% | 25.58+425.3% | 4.87-75.9% | 20.23-39.4% | 33.38+263.6% | 9.18+34.0% | 6.85 |
| Net Change in Cash | 25.73 | 276.56 | -3.41-167.0% | 5.09 | -25.28-1238.7% | 2.22-92.3% | 28.77 | -0.65 | -2.34 |
| Free Cash Flow | -146.29 | -81.54 | -41.53 | -27.64-1871.8% | 1.56 | -18.01 | -10.60 | -6.82 | -14.18 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price to Free Cash Flow ratio | - | - | - | - | 60.87 | - | - | - | - |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 197.58+100.4% | 237.93+93.8% | 278.61+92.4% | 318.13+110.0% | 98.57+15.9% | 122.80+316.8% | 144.78+262.7% | 151.52+283.7% |
| Short Term Receivables | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.06-99.4% | 0.06-85.4% | 0.06-83.8% | 0.06-83.8% | 10.370.0% |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 4.67+100.4% | 4.19+229.9% | 4.48+217.7% | 4.75+216.7% | 2.33+497.4% | 1.27+51.2% | 1.41+24.8% | 1.50+50.0% |
| Total Current Assets | 202.25+100.3% | 242.13+95.1% | 283.09+93.6% | 322.94+97.6% | 100.95+17.6% | 124.13+304.7% | 146.25+253.2% | 163.39+221.3% |
| Net Property, Plant & Equipment | 124.74+399.0% | 124.96+1299.3% | 41.66+473.8% | 31.85+363.6% | 25.00+267.1% | 8.93+22.5% | 7.26-6.2% | 6.87-9.7% |
| Total Investments and Advances | 0.96 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Assets | - | - | - | 4.00 | - | - | - | - |
| Other Assets | 2.42+393.9% | 1.65+223.5% | 1.53+512.0% | 1.16+427.3% | 0.49+53.1% | 0.51+59.4% | 0.25-13.8% | 0.22-18.5% |
| Total Assets | 330.37+161.3% | 368.74+176.1% | 326.28+112.2% | 359.95+111.1% | 126.44+36.0% | 133.57+248.9% | 153.77+211.0% | 170.48+190.3% |
| Short Term Debt Incl. Current Port. of LT Debt | 1.52-56.6% | 1.49-64.8% | 7.18+754.8% | 3.62+336.1% | 3.50+332.1% | 4.23+435.4% | 0.84+9.1% | 0.83+10.7% |
| Accounts Payable | 3.05+12.1% | 3.08-36.0% | 3.93-25.1% | 1.65-79.9% | 2.72-58.3% | 4.81-22.0% | 5.25-16.0% | 8.19+31.0% |
| Other Current Liabilities | 25.33+15.5% | 28.39+46.6% | 22.53+38.7% | 30.56+154.7% | 21.93+67.0% | 19.36+25.8% | 16.24-16.1% | 12.00-50.6% |
| Total Current Liabilities | 29.90+6.2% | 32.96+16.1% | 33.64+50.6% | 35.84+70.4% | 28.15+37.5% | 28.40+27.1% | 22.34-15.3% | 21.03-32.7% |
| Long Term Debt | 90.71+529.1% | 89.56+47036.8% | 13.94+268.8% | 14.32+258.9% | 14.42+242.5% | 0.19-95.7% | 3.78-18.4% | 3.99-17.9% |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | - | - | - | 4.00 | - | - | - | - |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 120.61+183.3% | 122.52+328.5% | 47.58+82.2% | 54.15+116.4% | 42.57+72.4% | 28.59+6.8% | 26.12-15.8% | 25.02-30.8% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 209.76+150.1% | 246.22+134.5% | 278.70+118.3% | 305.79+110.2% | 83.87+22.9% | 104.98+812.9% | 127.65+592.6% | 145.46+543.6% |
| Total Shareholders Equity | 209.76+150.1% | 246.22+134.5% | 278.70+118.3% | 305.79+110.2% | 83.87+22.9% | 104.98+812.9% | 127.65+592.6% | 145.46+543.6% |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 209.76+150.1% | 246.22+134.5% | 278.70+118.3% | 305.79+110.2% | 83.87+22.9% | 104.98+812.9% | 127.65+592.6% | 145.46+543.6% |
| Total Liabilities & Stockholders Equity | 330.37+161.3% | 368.74+176.1% | 326.28+112.2% | 359.95+111.1% | 126.44+36.0% | 133.57+248.9% | 153.77+211.0% | 170.48+190.3% |
| Book Value Per Share per share | 3.61+97.3% | 4.24+84.3% | 4.83+73.1% | 5.33+67.1% | 1.83+8.3% | 2.30+538.9% | 2.79+381.0% | 3.19+337.0% |
| Tangible Book Value Per Share per share | 3.61+97.3% | 4.24+84.3% | 4.83+73.1% | 5.33+67.1% | 1.83+8.3% | 2.30+538.9% | 2.79+381.0% | 3.19+337.0% |
| Full-Time Employees people | - | - | - | 231+44.4% | - | - | - | 160+56.9% |
| Price to Book Ratio ratio | 2.84 | 4.98 | 5.70 | 15.73 | 3.14 | 3.55 | 2.97 | 8.15 |
| Return on Assets % | -64.58 | -51.53 | -47.74 | -39.61 | -74.74 | -81.44 | -54.19 | -35.31 |
| Return on Equity % | -100.47 | -73.70 | -56.40 | -46.56 | -107.79 | -120.15 | -75.39 | -48.16 |
| Return on Invested Capital % | -14.20 | -12.13 | -11.60 | -9.43 | -25.00 | -24.64 | -18.56 | -4.76 |
| Quick Ratio ratio | 6.77 | 7.35 | 8.42 | 9.01 | 3.59 | 4.37 | 6.55 | 7.77 |
| Current Ratio ratio | 6.77 | 7.35 | 8.42 | 9.01 | 3.59 | 4.37 | 6.55 | 7.77 |
Cash flow, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -42.66 | -40.73 | -33.94 | -30.17 | -24.57 | -25.91 | -24.39 | -7.12 |
| Depreciation | 0.90+83.7% | 0.56+14.3% | 0.53+29.3% | 0.50+31.6% | 0.49+36.1% | 0.49+36.1% | 0.41+24.2% | 0.38+22.6% |
| Other Funds (Non Cash) | 7.35+67.8% | 6.72+85.1% | 6.19+5.5% | 7.26+203.8% | 4.38+114.7% | 3.63+69.6% | 5.87+80.1% | 2.39+29.2% |
| Funds from Operations | -34.40 | -33.45 | -27.21 | -22.41 | -19.69 | -21.79 | -18.11 | -4.35-410.7% |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -1.29-13000.0% | 1.97+18.0% | -2.04-117.5% | -1.16 | 0.01 | 1.67 | 11.68+136.4% | -10.45 |
| Cash from Operating Activities | -35.69 | -31.49 | -29.25 | -23.57 | -19.69 | -20.12 | -6.43 | -14.80 |
| Capital Expenditures | -4.52 | -5.90 | -10.75 | -5.12 | -4.01 | -1.45 | -1.14 | -0.73 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.02 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 64.40+222.6% | -42.95-368.4% | -143.89-674.9% | 48.21 | 19.96+868.9% | 16.00+8.3% | 25.03 | -122.65 |
| Purchase of Investments | -31.48 | -75.95 | -174.89 | -15.00 | -58.21 | -60.00 | -18.18 | -139.36 |
| Sale Or Maturity of Investments | 95.87+22.6% | 33.00-56.6% | 31.00-28.3% | 63.21+278.1% | 78.18+257.6% | 76.00+146.4% | 43.21+77.3% | 16.72-14.9% |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 59.90+275.5% | -48.76-435.1% | -154.64-747.3% | 43.09 | 15.95+697.5% | 14.55-1.0% | 23.89 | -123.38 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.09+800.0% | 2.10+10400.0% | 1.47+2840.0% | 248.82+206.8% | 0.01-100.0% | 0.02-99.0% | 0.05-97.8% | 81.09+250.0% |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.09+800.0% | 2.10+10400.0% | 1.47+2840.0% | 248.82+206.8% | 0.01-100.0% | 0.02-99.0% | 0.05-97.8% | 81.09+250.0% |
| Proceedsfrom Stock Options | 0.00 | 0.00 | 0.00 | 237.03+193.2% | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 80.84+249.1% |
| Issuance or Reduction of Debt, Net | 0.00 | -6.34 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | -6.34 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | -6.34 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 0.09+800.0% | -4.24-21300.0% | 1.47+2840.0% | 248.82+206.8% | 0.01-100.0% | 0.02-99.0% | 0.05-97.8% | 81.09+250.0% |
| Net Change in Cash | 24.30 | -84.49 | -182.43-1141.9% | 268.34 | -3.73-106.5% | -5.55-224.2% | 17.51 | -57.09-1099.8% |
| Free Cash Flow | -40.21 | -37.39 | -40.00 | -28.69 | -23.70 | -21.57 | -7.57 | -15.53 |
Revenue breakdown
USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.
| Name | 2024 | 2024 share |
|---|---|---|
| Pharmaceutical Preparations | 22.27 | 100.0% |
| Total | 22.27 | 100.0% |
| Name | 2024 | 2024 share |
|---|---|---|
| United States | 22.27 | 100.0% |
| Total | 22.27 | 100.0% |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 35.64% | 18.8M | 52.7M | 5.95M |
| 2026-10-15 | 37.72% | 19.9M | 52.7M | 6.98M |
| 2026-09-30 | 35.76% | 18.8M | 52.7M | 6.79M |
| 2026-09-15 | 37.38% | 19.7M | 52.7M | 6.46M |
| 2026-08-31 | 42.13% | 22.2M | 52.7M | 5.97M |
| 2026-08-14 | 33.74% | 17.8M | 52.6M | 4.20M |
| 2026-07-31 | 30.56% | 16.0M | 52.3M | 2.61M |
| 2026-07-15 | 29.78% | 15.6M | 52.3M | 1.22M |
| 2026-06-30 | 28.18% | 14.7M | 52.3M | 1.17M |
| 2026-06-15 | 22.38% | 11.7M | 52.3M | 1.08M |
| 2026-05-29 | 21.16% | 11.1M | 52.3M | 1.24M |
| 2026-05-15 | 20.87% | 10.9M | 52.3M | 1.31M |
| 2026-04-30 | 20.09% | 10.5M | 52.3M | 1.24M |
| 2026-04-15 | 19.31% | 10.0M | 52.0M | 1.31M |
| 2026-03-31 | 19.14% | 9.9M | 51.6M | 1.38M |
| 2026-03-13 | 14.22% | 7.3M | 51.6M | 1.31M |
| 2026-02-27 | 14.11% | 6.9M | 48.8M | 2.55M |
| 2026-02-13 | 13.58% | 6.6M | 48.8M | 2.69M |
| 2026-01-30 | 11.97% | 5.9M | 48.9M | 2.84M |
| 2026-01-15 | 10.45% | 5.1M | 48.9M | 2.81M |
Option chain
Expiry 2026-11-13 · underlying 10.25, quoted 13 Nov 07:42 ET · ATM 10.00
Option quotes 12 Nov 15:58 ET. A date on a row is older than the last session (12 Nov). 41 rows.
Implied move 17.80% into expiry (call 1.175 + put 0.650 = 1.825 on 10.25)
Put/call open interest 0.34 (4,113 puts / 11,971 calls) · Put/call volume 0.26 (278 puts / 1,075 calls)
IV change is points against the prior close.
| Type | Strike | Money | Bid | Ask | Last | Chg | IV | Open int | Volume | Last size | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| call | 1.00 | ITM | 7.60 | 11.40 | 9.51 | +0.56 | - | 2 | 2 | 1 | 0.993 | -0.158 | 0.000 |
| put 1 Jan | OTM | 0.00 | 0.05 | 0.00 | 0.00 | - | 0 | 0 | 0 | -0.007 | -0.158 | 0.000 | |
| call | 2.00 | ITM | 6.50 | 10.50 | 8.32 | +0.27 | - | 6 | 3 | 1 | 0.989 | -0.165 | 0.000 |
| put 1 Jan | OTM | 0.00 | 0.05 | 0.00 | 0.00 | - | 0 | 0 | 0 | -0.012 | -0.125 | 0.000 | |
| call 11 Nov | 2.50 | ITM | 6.20 | 10.00 | 7.63 | 0.00 | - | 3 | 0 | 0 | 0.986 | -0.166 | 0.000 |
| put 1 Jan | OTM | 0.00 | 4.90 | 0.00 | 0.00 | - | 0 | 0 | 0 | -0.014 | -0.166 | 0.000 | |
| call 11 Nov | 3.00 | ITM | 5.60 | 9.50 | 7.07 | 0.00 | - | 3 | 0 | 0 | 0.984 | -0.165 | 0.000 |
| put 9 Nov | OTM | 0.00 | 0.05 | 0.02 | 0.00 | - | 31 | 0 | 0 | -0.015 | -0.135 | 0.000 | |
| call 11 Nov | 3.50 | ITM | 5.00 | 9.00 | 6.55 | 0.00 | - | 0 | 0 | 0 | 0.982 | -0.164 | 0.000 |
| put 10 Nov | OTM | 0.00 | 4.90 | 0.05 | 0.00 | - | 68 | 0 | 0 | -0.018 | -0.164 | 0.000 | |
| call 11 Nov | 4.00 | ITM | 4.50 | 8.50 | 6.14 | 0.00 | - | 4 | 0 | 0 | 0.979 | -0.162 | 0.000 |
| put 11 Nov | OTM | 0.00 | 1.80 | 0.04 | 0.00 | - | 295 | 0 | 0 | -0.021 | -0.162 | 0.000 | |
| call 11 Nov | 4.50 | ITM | 4.00 | 8.00 | 5.45 | 0.00 | - | 2 | 0 | 0 | 0.977 | -0.160 | 0.000 |
| put 11 Nov | OTM | 0.00 | 4.90 | 0.05 | 0.00 | - | 3 | 0 | 0 | -0.023 | -0.159 | 0.000 | |
| call | 5.00 | ITM | 3.60 | 7.40 | 5.30 | +0.50 | - | 1 | 1 | 1 | 0.973 | -0.157 | 0.000 |
| put | OTM | 0.00 | 0.05 | 0.10 | +0.05 | - | 1,552 | 1 | 1 | -0.038 | -0.217 | 0.000 | |
| call 11 Nov | 5.50 | ITM | 3.20 | 7.00 | 4.37 | 0.00 | - | 2 | 0 | 0 | 0.970 | -0.154 | 0.000 |
| put | OTM | 0.00 | 0.05 | 0.10 | +0.09 | 1003.9% 0.0 | 16 | 4 | 1 | -0.064 | -0.349 | 0.001 | |
| call | 6.00 | ITM | 2.50 | 6.50 | 4.25 | -0.75 | - | 25 | 4 | 4 | 0.966 | -0.150 | 0.000 |
| put | OTM | 0.00 | 0.05 | 0.05 | 0.00 | 892.5% 0.0 | 76 | 5 | 2 | -0.072 | -0.339 | 0.001 | |
| call | 6.50 | ITM | 2.00 | 6.00 | 3.75 | +0.35 | 2605.3% +1920.4 | 0 | 4 | 4 | 0.940 | -0.241 | 0.001 |
| put | OTM | 0.00 | 1.15 | 0.10 | -0.65 | 686.3% 0.0 | 23 | 10 | 3 | -0.060 | -0.242 | 0.001 | |
| call | 7.00 | ITM | 2.35 | 3.50 | 3.10 | -1.16 | 676.4% +81.7 | 1,406 | 22 | 1 | 0.931 | -0.233 | 0.001 |
| put | OTM | 0.05 | 0.10 | 0.10 | -0.02 | 654.9% 0.0 | 396 | 8 | 1 | -0.087 | -0.298 | 0.001 | |
| call | 7.50 | ITM | 1.45 | 4.40 | 3.25 | +0.25 | 1016.0% +293.2 | 19 | 4 | 1 | 0.859 | -0.476 | 0.001 |
| put 11 Nov | OTM | 0.00 | 0.95 | 0.40 | 0.00 | 723.0% 0.0 | 63 | 0 | 0 | -0.141 | -0.475 | 0.001 | |
| call | 8.00 | ITM | 1.80 | 3.90 | 2.85 | +0.85 | 1226.6% +608.0 | 76 | 3 | 1 | 0.837 | -0.448 | 0.001 |
| put | OTM | 0.05 | 1.30 | 0.15 | -0.12 | 618.9% 0.0 | 120 | 41 | 1 | -0.163 | -0.447 | 0.001 | |
| call | 8.50 | ITM | 0.95 | 3.60 | 3.00 | +0.80 | 1449.0% +757.0 | 32 | 4 | 2 | 0.767 | -0.621 | 0.002 |
| put | OTM | 0.10 | 0.65 | 0.25 | -0.05 | 693.5% 0.0 | 217 | 12 | 10 | -0.233 | -0.623 | 0.001 | |
| call | 9.00 | ITM | 0.60 | 3.10 | 1.70 | -0.80 | 1349.8% +771.0 | 148 | 3 | 3 | 0.728 | -0.565 | 0.002 |
| put | OTM | 0.00 | 0.55 | 0.25 | -0.22 | 577.6% 0.0 | 1,048 | 148 | 1 | -0.272 | -0.562 | 0.002 | |
| call | 9.50 | ITM | 0.50 | 4.90 | 1.70 | +1.69 | 1473.0% +653.2 | 99 | 6 | 3 | 0.651 | -0.891 | 0.002 |
| put | OTM | 0.15 | 2.00 | 0.20 | -0.25 | 715.2% -104.8 | 142 | 1 | 1 | -0.349 | -0.891 | 0.002 | |
| call | 10.00 | ATM | 0.25 | 2.10 | 0.95 | -0.90 | 611.9% +19.2 | 5,499 | 361 | 5 | 0.589 | -0.678 | 0.002 |
| put | ATM | 0.30 | 1.00 | 0.70 | -0.20 | 580.8% -11.9 | 24 | 21 | 1 | -0.411 | -0.676 | 0.002 | |
| call | 10.50 | OTM | 0.00 | 2.30 | 0.70 | -0.65 | 442.6% -298.3 | 228 | 15 | 7 | 0.542 | -0.863 | 0.002 |
| put | ITM | 0.55 | 2.55 | 1.35 | +0.10 | 1242.0% +323.7 | 24 | 27 | 1 | -0.436 | -1.061 | 0.002 | |
| call | 11.00 | OTM | 0.40 | 0.60 | 0.40 | -0.98 | 461.1% -82.7 | 926 | 160 | 1 | 0.442 | -0.631 | 0.002 |
| put 11 Nov | ITM | 0.15 | 2.60 | 1.15 | 0.00 | 1099.7% +556.2 | 11 | 0 | 0 | -0.558 | -0.629 | 0.002 | |
| call | 11.50 | OTM | 0.00 | 2.75 | 0.55 | -0.61 | 542.2% 0.0 | 42 | 19 | 4 | 0.375 | -0.604 | 0.002 |
| put 1 Jan | ITM | 0.45 | 4.90 | 0.00 | 0.00 | 2134.8% +1593.8 | 0 | 0 | 0 | -0.625 | -0.600 | 0.002 | |
| call 11 Nov | 12.00 | OTM | 0.00 | 4.10 | 0.75 | 0.00 | 612.5% 0.0 | 239 | 0 | 0 | 0.347 | -0.663 | 0.002 |
| put 1 Jan | ITM | 0.50 | 4.90 | 0.00 | 0.00 | 1935.2% +1322.5 | 0 | 0 | 0 | -0.653 | -0.662 | 0.002 | |
| call | 12.50 | OTM | 0.00 | 1.05 | 0.40 | -0.45 | 677.6% 0.0 | 2 | 1 | 1 | 0.325 | -0.715 | 0.002 |
| put 1 Jan | ITM | 1.20 | 4.90 | 0.00 | 0.00 | 1739.9% +1062.6 | 0 | 0 | 0 | -0.675 | -0.713 | 0.002 | |
| call | 13.00 | OTM | 0.00 | 0.90 | 0.30 | -0.50 | 617.4% 0.0 | 461 | 211 | 3 | 0.254 | -0.582 | 0.002 |
| put 1 Jan | ITM | 1.60 | 5.50 | 0.00 | 0.00 | 1860.6% +1243.2 | 0 | 0 | 0 | -0.746 | -0.580 | 0.002 | |
| call 11 Nov | 13.50 | OTM | 0.05 | 4.90 | 0.52 | 0.00 | 668.0% 0.0 | 10 | 0 | 0 | 0.241 | -0.610 | 0.002 |
| put 1 Jan | ITM | 1.90 | 6.00 | 0.00 | 0.00 | 1920.6% +1251.0 | 0 | 0 | 0 | -0.759 | -0.611 | 0.002 | |
| call | 14.00 | OTM | 0.00 | 1.45 | 0.22 | -0.28 | 718.1% 0.0 | 66 | 1 | 1 | 0.230 | -0.640 | 0.001 |
| put 1 Jan | ITM | 2.50 | 6.20 | 0.00 | 0.00 | 1822.2% +1104.1 | 0 | 0 | 0 | -0.770 | -0.638 | 0.001 | |
| call | 14.50 | OTM | 0.00 | 4.10 | 0.11 | -0.59 | 763.6% 0.0 | 1 | 1 | 1 | 0.220 | -0.665 | 0.001 |
| put 10 Nov | ITM | 2.90 | 6.70 | 6.12 | 0.00 | 1874.2% +1111.2 | 0 | 0 | 0 | -0.780 | -0.662 | 0.001 | |
| call | 15.00 | OTM | 0.00 | 0.45 | 0.10 | -0.46 | 804.7% 0.0 | 321 | 3 | 2 | 0.212 | -0.684 | 0.001 |
| put 10 Nov | ITM | 2.55 | 7.40 | 6.57 | 0.00 | 2024.6% +1219.7 | 0 | 0 | 0 | -0.788 | -0.683 | 0.001 | |
| call 1 Jan | 15.50 | OTM | 0.00 | 4.90 | 0.00 | 0.00 | 847.1% 0.0 | 0 | 0 | 0 | 0.206 | -0.708 | 0.001 |
| put 1 Jan | ITM | 3.90 | 7.40 | 0.00 | 0.00 | 1818.5% +972.0 | 0 | 0 | 0 | -0.794 | -0.705 | 0.001 | |
| call 1 Jan | 16.00 | OTM | 0.00 | 4.90 | 0.00 | 0.00 | 883.3% 0.0 | 0 | 0 | 0 | 0.199 | -0.724 | 0.001 |
| put 1 Jan | ITM | 3.50 | 8.40 | 0.00 | 0.00 | 2121.4% +1235.8 | 0 | 0 | 0 | -0.801 | -0.725 | 0.001 | |
| call 1 Jan | 16.50 | OTM | 0.00 | 4.90 | 0.00 | 0.00 | 922.2% 0.0 | 0 | 0 | 0 | 0.194 | -0.745 | 0.001 |
| put 1 Jan | ITM | 4.00 | 8.90 | 0.00 | 0.00 | 2164.5% +1242.3 | 0 | 0 | 0 | -0.806 | -0.743 | 0.001 | |
| call | 17.00 | OTM | 0.00 | 4.90 | 0.05 | -0.10 | 957.2% 0.0 | 2 | 1 | 1 | 0.189 | -0.762 | 0.001 |
| put 10 Nov | ITM | 4.90 | 9.00 | 9.02 | 0.00 | 1999.3% +1042.7 | 1 | 0 | 0 | -0.811 | -0.759 | 0.001 | |
| call | 18.00 | OTM | 0.00 | 0.50 | 0.05 | -0.15 | 719.6% 0.0 | 2,346 | 246 | 3 | 0.072 | -0.289 | 0.001 |
| put 10 Nov | ITM | 6.50 | 10.00 | 10.00 | 0.00 | 2073.6% +1052.9 | 3 | 0 | 0 | -0.819 | -0.787 | 0.001 | |
| call 1 Jan | 19.00 | OTM | 0.00 | 0.00 | 0.00 | 0.00 | - | 0 | 0 | 0 | - | - | - |
| put 1 Jan | ITM | 0.00 | 0.00 | 0.00 | 0.00 | - | 0 | 0 | 0 | - | - | - | |
| call 1 Jan | 20.00 | OTM | 0.00 | 0.00 | 0.00 | 0.00 | - | 0 | 0 | 0 | - | - | - |
| put 1 Jan | ITM | 0.00 | 0.00 | 0.00 | 0.00 | - | 0 | 0 | 0 | - | - | - | |
| call 1 Jan | 21.00 | OTM | 0.00 | 0.00 | 0.00 | 0.00 | - | 0 | 0 | 0 | - | - | - |
| put 1 Jan | ITM | 0.00 | 0.00 | 0.00 | 0.00 | - | 0 | 0 | 0 | - | - | - | |
| call 1 Jan | 22.00 | OTM | 0.00 | 0.00 | 0.00 | 0.00 | - | 0 | 0 | 0 | - | - | - |
| put 1 Jan | ITM | 0.00 | 0.00 | 0.00 | 0.00 | - | 0 | 0 | 0 | - | - | - |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-10 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-11-10 | 8-K | Current report | 2026-11-10 | SEC |
| 2026-10-14 | SCHEDULE 13G/A | SEC | ||
| 2026-09-14 | SCHEDULE 13G | SEC | ||
| 2026-08-24 | 8-K | Current report | 2026-08-24 | SEC |
| 2026-08-19 | SCHEDULE 13G | SEC | ||
| 2026-08-14 | SCHEDULE 13G/A | SEC | ||
| 2026-08-14 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-13 | 8-K | Current report | 2026-08-13 | SEC |
| 2026-08-07 | SCHEDULE 13G | SEC | ||
| 2026-08-03 | SCHEDULE 13G | SEC | ||
| 2026-07-30 | 8-K | Current report | 2026-07-29 | SEC |
| 2026-07-29 | 8-K | Current report | 2026-07-29 | SEC |
| 2026-07-14 | 8-K | Current report | 2026-07-09 | SEC |
| 2026-06-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-25 | SEC |
| 2026-06-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-25 | SEC |
| 2026-06-26 | 8-K | Current report | 2026-06-26 | SEC |
| 2026-06-24 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-22 | SEC |
| 2026-06-24 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-22 | SEC |
| 2026-06-08 | 8-K | Current report | 2026-06-04 | SEC |
| 2026-05-28 | 4 | Statement of changes in beneficial ownership of securities | 2026-05-26 | SEC |
| 2026-05-28 | 3 | Initial statement of beneficial ownership of securities | 2026-05-25 | SEC |
| 2026-05-19 | 144/A | SEC | ||
| 2026-05-19 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-05-19 | 4 | Statement of changes in beneficial ownership of securities | 2026-05-18 | SEC |
| 2026-05-14 | 4 | Statement of changes in beneficial ownership of securities | 2026-05-13 | SEC |
| 2026-05-13 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-03-31 | SEC |
| 2026-05-12 | 8-K | Current report | 2026-05-12 | SEC |
| 2026-05-07 | 8-K | Current report | 2026-05-07 | SEC |
| 2026-05-04 | 4 | Statement of changes in beneficial ownership of securities | 2026-05-01 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 1.52M | 6 |
| 2026-05 | 0 | 0 | 1.59M | 2 |
| 2026-04 | 0 | 0 | 1.91M | 2 |
| 2026-03 | 0 | 0 | 3.35M | 3 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| BlackRock, Inc. | 7.16% |
| TANG CAPITAL MANAGEMENT LLC | 7.08% |
| MONTANOVA CAPITAL, LLC | 7.07% |
| STATE STREET CORP | 5.19% |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.97% |
| GOLDMAN SACHS GROUP INC | 2.73% |
| RA CAPITAL MANAGEMENT, L.P. | 2.60% |
| UBS Group AG | 2.41% |
| Boxer Capital Management, LLC | 2.41% |
| GEODE CAPITAL MANAGEMENT, LLC | 1.96% |
Funds
| Fund | % owned |
|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3.76% |
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 2.86% |
| iShares Russell 2000 ETF | 2.42% |
| VANGUARD EXTENDED MARKET INDEX FUND | 1.02% |
| Fidelity Small Cap Index Fund | 1.02% |
| iShares Russell 2000 Growth ETF | 0.86% |
| VANGUARD RUSSELL 2000 INDEX FUND | 0.53% |
| Select Pharmaceuticals Portfolio | 0.40% |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 0.33% |
| VANGUARD HEALTH CARE INDEX FUND | 0.24% |
OakChart. CAPR. Cached 15 minutes. Terms